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1. Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disease among the 
elderly. While sporadic PD constitutes 99% of the cases, the remaining 1% is of genetic 
origin. The neuropathological hallmarks of PD are progressive degeneration of 
dopaminergic (DA) neurons and presence of Lewy neurites and Lewy bodies (LBs) - 
intracytoplasmic proteinaceous inclusions that contain -synuclein (SYN), synphilin-1, 
components of the ubiquitin proteasomal pathway and parkin (Dawson, 2006). The loss of 
DA neurons in substantia nigra pars compacta (SNpc) results in decreased signalling in the 
striatum thereby giving rise to motor defects like resting tremor, bradykinesia, rigidity and 
posture instability. Besides DA neuronal loss, microglial activation and increased astroglial 
and lymphocyte infiltration also occur in PD. A role for inflammation in PD has been 
inferred from the identification of human leukocyte antigen (HLA)-DR positive reactive 
microglia in the brains of PD patients (McGeer et al., 1988). Additionally, levels of pro-
inflammatory cytokines like IL-6, IL-1, TNF have been found to be elevated in the blood 
and cerebrospinal fluid (CSF) of PD patients (Nagatsu & Sawada, 2005; Dawson, 2006) 
Although these inflammatory components might serve as useful biomarkers, the aetiology 
of striatal DA degeneration still remains enigmatic.  
In the last decade, identification of mutations in several distinct genes (LRRK2, parkin, 
PINK1, DJ-1, -synuclein, MAPT, UCHL1 etc) linked to different forms of familial 
Parkinsonism has imparted a new direction to understanding PD pathogenesis (Tong & 
Shen, 2009). The question as to how seemingly divergent genes cause PD still remains 
unanswered, as there is no common molecular pathway involving these gene products. 
While parkin, -synuclein (SYN) and ubiquitin C-terminal hydrolase L1 (UCHL1) are 
functionally associated with the cellular ubiquitin proteasomal system (UPS), DJ-1 and 
PINK1 protect against oxidative stress and mitochondrial dysfunction. More recently, 
microarray analysis of SNpc from parkinsonian brain (Mandel et al., 2005) has shown that 68 
genes related to protein degradation, signal transduction, dopaminergic transmission, iron 
transport and glycolysis are downregulated. Prominent among these are the protein 
chaperone HSC-70, subunits of the UPS and SKP1A, a member of the E3 ubiquitin ligase 
complex. Therefore, it is most likely that impairment in energy metabolism and/or 
alterations in UPS are the underlying mechanisms for PD pathogenesis (Eriksen et al., 2005; 
Mandel et al., 2005). 
Current PD treatment regimes can be divided into three categories: symptomatic, protective 
and restorative. Only symptomatic treatment via the administration of L-dopa and other 
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drugs affecting neurological transmission have shown efficacy. However, side effects like 
dyskinesia, motor fluctuations and neurological complications limit their long-term use 
(Gold & Nutt, 2002). The neuroimmunophilins ligands (NILs) are a promising new class of 
drugs for treatment of PD as well as other neurodegenerative diseases. NILs are derived 
from the immunosuppressant, FK506 (tacrolimus) and exert their activity not via any 
cellular mechanism involving the immune system but by binding to a group of proteins 
termed FK506 binding proteins (FKBPs). When compared to the immune system, FKBP 
expression levels are highly enriched (10-50 fold greater) in both the central and peripheral 
nervous system. In this chapter, we review our current understanding of the role of FKBPs 
in the nervous system with an emphasis on the protein partners that interface with FKBPs 
inside cells. For brevity, we limit our discussions to FKBPs that are enriched in the nervous 
systems and may have important role in Parkinson’s disease pathogenesis. We also 
highlight the mode of action of the NILs with the hope that knowledge of such interaction 
will enable rationale design of new drugs with improved efficacy for treatment of 
Parkinson’s disease as well as other neurodegenerative disorders. 
2. Role of FKBPs in the nervous system 
FKBPs together with cyclophilins (CyPs) comprise a family of phylogenetically conserved 
immunophilins that have peptidyl prolyl isomerase activity (PPIase; EC 5.2.1.8), producing 
the cis-trans isomerization of X-Pro peptide bond, an essential but rate-limiting step in the 
protein folding process (Barik, 2006). Initial isolation and purification of immunophilins 
were based on their differential affinity towards the principal immunosuppressant drugs - 
rapamycin, FK506 and cyclosporin A (CsA). While CyPs bind to only CsA, FKBPs have 
affinities for both FK506 and rapamycin. Immunosuppressive activity mediated by these 
drugs is brought about by their binding to the cognate immunophilins. The FK506/FKBP or 
CsA/CyP binary complexes bind to the Ca2+/calmodulin dependent protein 
serine/threonine phosphatase, calcineurin (CaN) and inhibit its phosphatase activity. The 
resulting FKBP-FK506-CaN ternary complex cannot dephosphorylate the key transcription 
factor, nuclear factor of activated T-cells (NF-AT). Inactive NF-AT remains in the cytoplasm 
thereby preventing interleukin-2 (IL-2) secretion (Figure 1). Consequently, both T-cell 
activation and proliferation is inhibited. On the other hand, FKBP-rapamycin complex exerts 
immunosuppression by inhibiting the serine/threonine kinase activity of mammalian target 
of rapamycin (mTOR) (Sharma et al., 1994).  
The role of FKBPs in the nervous system was initiated by observations that the brain is 
abundantly enriched in CyPs and FKBPs (Maki et al., 1990; Steiner et al., 1992; Dawson et al., 
1994). The importance of immunophilins in the nervous system was firmly established from 
studies showing that FK506 potently (as low as 0.1 nM) increases neurite outgrowth in both 
PC-12 (Lyons et al., 1994) and SH-SY5Y cell culture models as well as in primary cultures of 
chick dorsal root ganglion and hippocampal neurons (Hamilton and Steiner, 1998). Efforts to 
explain this neurotrophic effect focussed on the calcineurin-dependent pathway involving the 
CaN substrate, GAP-43 (growth-associated protein-43). GAP-43 selectively localizes to 
developing neurons and its phosphorylation is known to enhance its neurite extension activity 
(Meiri et al., 1991). Though initially tenable, the hypothesis was challenged when it was shown 
that both CsA (Gold, 1997) and non-immunosuppressive (hence non-calcineurin binding) 
derivatives of FK506 exhibit neurotrophic effect with similar potencies as that of FK506. 
Therefore, it is most likely that nerve growth proceeds via a calcineurin-independent pathway. 
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Fig. 1. Immunosuppressive effect of neuroimmunophilin ligands: T-cell receptor activation 
leads to a rapid increase in intracellular calcium levels with concomitant activation of the 
Ca2+/calmodulin-dependent phosphatase, calcineurin (CaN). Active CaN dephosphorylates 
the transcription factor NF-AT, allowing its nuclear translocation and thereby upregulating 
IL-2 expression. Addition of FK506 or CsA results in formation of FKBP-FK506-CaN/CyP-
CsA-CaN ternary complexes that inhibits CaN-dependent NF-AT dephosphorylation, as a 
result T-cell activation and IL-2 secretion does not occur.  
When FK506-treated brain lysates were probed for proteins with increased phosphorylation 
levels, one of the identified targets was neuronal nitric oxide synthase (nNOS).  In the brain, 
nNOS catalyzes the formation of nitric oxide (NO) from arginine and its catalytic activity is 
inhibited by phosphorylation. Following cerebral vascular occlusion, there is a massive 
increase in the excitatory neurotransmitter glutamate. Elevated glutamate levels, acting 
through the N-methyl-D-aspartate (NMDA) receptor, activates nNOS resulting in increased 
NO formation and neurotoxicity (Figure 2). Toxicity may involve NO itself or its 
combination with superoxide free radical (O2¯) to form peroxy-nitrite that decomposes to 
hydroxide (OH¯) and NO2 (NO2¯) free radicals with subsequent cellular damage by 
oxidation of nucleic acids, proteins and membrane lipids (Snyder, 1992). By enhancing 
phospho nNOS levels, FKBPs inhibit NO formation and thereby attenuate glutamate toxicity 
following vascular stroke (Snyder et al., 1998). Contrary to nerve regeneration, FKBP-
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mediated neuroprotection proceeds via calcineurin inhibition as anti-stroke effects were also 
seen with CsA. 
 
 
Fig. 2. NILs regulate neurotoxicity and neurotransmitter release: Glutamate-mediated influx 
of calcium through the NMDA receptor activates calcineurin (CaN) that in turn 
dephosphorylates nNOS and increases its catalytic activity. nNOS activation leads to 
increased NO formation and subsequent neurotoxicity and neurotransmitter release. 
FK506/CsA can counteract this neuronal toxicity by inhibiting CaN-dependent nNOS 
activation. Influx of Ca2+ also activates PKC and CaN that have opposing effect on 
phosphorylation state of the GTPase, dynamin I.  While PKC-mediated phosphorylation of 
dynamin I increases its GTPase activity and leads to increased neurotransmitter release, 
CaN dephosphorylates and inactivates dynamin I. By inhibiting CaN, FK506 and CsA 
enhances phospho-dynamin I levels and subsequent depolarization-evoked 
neurotransmitter release.   
FK506 has contradictory roles in neurotransmitter release - it inhibits NMDA induced 
neurotransmitter release while augmenting depolarization-induced release. Since 
neurotransmitter release proceeds via calcineurin-dependent pathway, this discrepancy in 
FK506 response can be attributed to the involvement of distinct calcineurin substrates, 
nNOS and dynamin I (Figure 2). FK506 reduces glutamate release from NMDA-stimulated 
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striatal synaptosomes as well as acetylcholine and dopamine release from PC12 cells that 
have been differentiated by NGF (Steiner et al., 1996). Similar reductions seen with the nNOS 
inhibitor, nitro-L-arginine, indicates that NO regulates neurotransmitter release in PC12 and 
synaptosomes. In presence of FK506 and CsA, inhibition of calcineurin and subsequent 
reduction of nNOS activity results in decreased NO levels and therefore reduced 
neurotransmitter release. 
In contrast, FK506 fails to inhibit potassium depolarization-evoked neurotransmitter release. 
Both CsA and L-683590 (FK506 analog that inhibits calcineurin), augment glutamate release 
from synaptosomes that have been treated with the K+-channel blocker, 4-aminopyridine. In 
this case, the bona fide calcineurin substrate, dynamin I and not nNOS is involved (Nichols et 
al., 1994). Dynamin I, a GTPase that regulates vesicular recycling, is active in its 
phosphorylated form; enhanced GTPase activity results in greater synaptic vesicular 
trafficking and increased rate of neurotransmitter release. CsA and FK506 mediated 
inhibition of calcineurin enhances dynamin I phosphorylation and hence its activity.  
FK506 and its derivatives have also shown neuroprotective activity in neuropathy models 
mimicking stroke and dementia. For example, FK506-mediated calcineurin inhibition 
protects against ischemic brain injury (Sharkey & Butcher, 1994), desensitizes NMDA 
receptors (Tong et al., 1995), prevents long-term depression (LTD) in rat hippocampus 
(Hodgkiss & Kelly, 1995) and modulates long-term potentiation (LTP) in rat visual cortex 
(Funauchi et al., 1994).  Stabilization of mitochondrial function was suggested to account for 
the anti-ischemic activities of FK506. FK506 does not target the mitochondrial potential 
transition pore (MTP) but prevents deterioration in mitochondrial respiration while 
maintaining cellular ATP levels and Ca2+ homeostasis.  Furthermore, the role of FKBPs in 
the central nervous system has been extensively probed using 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) induced lesions of 
dopaminergic neurons.  Both agents cause massive degeneration of nigrostriatal DA 
neurons thereby making MPTP and 6-OHDA treatment experimental paradigms for 
Parkinson’s disease (Gerlach et al., 1991). Treatment with GPI-1046, a FK506 analog was able 
to substantially recover the MPTP-damaged DA neurons as evidenced by increased tyrosine 
hydroxylase staining while rats lesioned with 6-OHDA showed morphological and 
functional recovery with increased striatal catecholamine levels and reduced amphetamine-
induced rotations (Steiner et al., 1997). 
How might immunophilin ligands exert their neurotrophic and neuroprotective actions? 
The data suggests that PPIase activity of FKBPs maybe involved but no conclusive 
evidence has been provided so far. Several studies have tried to identify the FKBP(s) 
involved and elucidate the mechanism-of-action. This has proved particularly difficult as 
(1) most of the FKBP family members bind FK506 or its derivatives, albeit with varying 
degrees of affinity; (2) activities of both FKBPs and the protein phosphatase, calcineurin 
are inhibited by FK506 and its analogues and (3) FKBPs perform multifarious roles in 
protein folding, translocation and regulation as well as have a wide range of 
tissue/organellar distribution. Initial studies implicated a role for FKBP12 as elevated 
mRNA and proteins levels were observed in 6-OHDA model of PD (Nilsson et al., 2007). 
Moreover, higher levels of FKBP12 have also been reported in brains of PD patients 
(Avramut & Achim, 2002). Therefore, a possible link between FKBPs and PD might stem 
from the increase in expression or redistribution of chaperone proteins in stress 
conditions. In addition to FKBP12, the human brain is enriched in FKBP38, FKBP51, 
FKBP52 and FKBP65 (Charters et al., 1994; Coss et al., 1998; Chambraud et al., 2010; Jinwal 
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et al., 2010). Collectively, these immunophilins enriched in the nervous system are termed 
neuroimmunophilins. In the following sections, we will discuss the role of only those 
neuroimmunophilins that may be important for PD pathogenesis.  
3. Molecular interacting partners of neuroimmunophilins 
The neuroprotective and neurotrophic functions observed with NILs together with studies 
showing that chaperone proteins like HSP70 can suppresses -synuclein (-SYN) mediated 
loss of dopaminergic neurons in Drosophila model of PD (Auluck et al., 2002; Muchowski, 
2002), posits that FKBPs may have important role(s) in preventing PD-associated 
neurodegeneration. FKBPs, together with other chaperones may convert the toxic 
conformations of misfolded proteins to non-toxic form that is tolerated by cells. 
Alternatively, they may prevent the formation of toxic pre-fibrillar intermediates, or 
accelerate their conversion to nontoxic, amorphous aggregates that can be degraded by the 
cellular proteolytic machinery. 
3.1 FKBPs interact with -synuclein both in vitro and in vivo 
-SYN is a small (140 amino acid) intrinsically disordered protein predominantly localized 
to the presynaptic terminals. -SYN regulates the functions of several other proteins - 
synphilin-1, parkin, tyrosine hydroxylase, dopamine transporter and phospholipase D, via 
stoichiometric protein-protein and protein-lipid interactions (Goedert, 2001; Ischiropoulos, 
2003).  In PD, -SYN aggregates into characteristic fibrillar -pleated structures in Lewy 
bodies. Besides LBs, -SYN also forms intermediate-state oligomers that when released from 
the neurons activate microglia leading to an increased production of ROS and 
proinflammatory cytokines (Glass et al., 2010). Activated microglia further amplifies this 
inflammatory response in a positive feedback loop. In -SYN, the ability of the central 
hydrophobic NAC (non A-component of amyloid plaques in Alzheimer’s disease) domain 
to aggregate is normally counteracted by the highly charged hydrophilic C-terminal 
domain. Interestingly, all 5 proline residues (Pro108, Pro117, Pro120, Pro128, Pro138) of -SYN are 
located at the C-terminal of the protein. Changes to the C-terminal domain through deletion, 
point mutations or via posttranslational modifications such as phosphorylation (Kragh et al., 
2009) expose the NAC domain leading to hydrophobic interaction driven aggregation. For 
example, the E3-ubiquitin ligase, parkin can protect against -SYN-induced toxicity by 
altering the phosphorylation levels of -SYN (Figure 3). By simultaneously reducing PLK2 
levels and activating PP2A, parkin decreases Ser87 and Ser129 phosphorylation thereby 
decreasing aggregation of phosphorylated -SYN in LBs (Khandelwal et al., 2010). The role 
of FKBPs in synucleinopathy has been probed both in vitro (Gerard et al., 2006) and in vivo 
(Gerard et al., 2010).  In vitro, fluorescence correlation spectroscopy (FCS) measurements 
showed that addition of FKBP12 accelerates -SYN aggregation into fibrillar structures that 
mimic aggregates formed in LBs. FKBP12 significantly alters the rate for both the nucleation 
and fibril formation stages (Gerard et al., 2008). Since FKBPs catalyze the cis-trans 
isomerization of X-Pro peptide bond, the importance of C-terminal proline residues of -
SYN was also investigated. Changing one or more proline residues to alanine increased the 
aggregation kinetics of mutant -SYN (Meuvis et al., 2010). Additionally, FKBP12 did not 
interact with a proline deficient -SYN mutant and this mutant was also found to be more 
structured.  
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Using a neuronal model of synucleinopathy in which α-SYN aggregation and cell death was 
induced by oxidative stress, Gerard and coworkers have shown that both FK506 and 
knockdown of FKBP12/FKBP52 can counter the effects of oxidative stress. Likewise, it was 
shown that overexpression of FKBP12 and -52 enhances α-SYN aggregation. FKBP52 was 
less potent than FKBP12 in inducing fibrillar aggregation. In vivo, FKBP12 was shown to 
colocalize with -SYN in the brain of A30P--SYN transgenic mice model. Furthermore, 
FK506 administration reduced both the -SYN aggregation in cells as well as increased 
survival of -SYN overexpressing neurons in the striatum. Collectively, these studies 
validate FKBPs as a novel target for PD. 
Besides -SYN, other interacting partners of FKBP12 identified from 6-OHDA treated rat 
model of PD include 1-cys peroxyredoxin, HSP70, 14-3-3 zeta, M2-type pyruvate kinase 
(PKM2), annexin A2 and -enolase (ENO1) (Nilsson et al., 2007). It has been known that 
levels of PKM2, 14-3-3 zeta and ENO1 are altered during neurodegenerative diseases like 
PD and Alzheimer’s (Poon et al., 2006).  
Given that FKBPs are chaperone proteins having important roles in protein folding, it is 
counterintuitive to note that the interaction between FKBP(s) and -SYN results in -SYN 
aggregation. Its is likely that -SYN inclusions may not result simply from precipitated 
misfolded protein but rather from an active process meant to sequester soluble misfolded 
proteins from the cellular milieu (Kopito, 2000). Accordingly, inclusion body formation 
might serve as a cellular defense mechanism aimed at removing toxic insoluble proteins. 
3.2 FKBP52 interacts with RET51 in a phosphorylation-dependent manner 
RET51, a tyrosine kinase (TK) receptor, has important roles in the development and 
maintenance of the nervous system. Recently, FKBP52 was found to be novel interacting 
partner for RET51 in a split ubiquitin two-hybrid screen (Fusco et al., 2010). Neurotrophins 
like NGF and glial-cell line derived neurotrophic factor (GDNF) promote the 
phosphorylation driven formation of RET51/FKBP52 complex; phosphorylation occurs on 
Tyr905 within the TK domain of RET51 and is a pre-requisite for complex formation. 
Association of RET51 with FKBP52 does not depend on HSP90 or other chaperones. The 
involvement of RET51 in PD comes from the genetic analysis of an early onset-PD patient 
heterozygous for mutations on both RET51 and FKBP52 genes (Fusco et al., 2010). Mutations 
on both proteins disrupt formation of RET51/FKBP52 complex and its downstream 
signaling pathway. The detail of this signaling mechanism remains to be elucidated. 
3.3 FKBP38 promotes trafficking of membrane channels 
FKBP38 is distributed to both the mitochondria (Shirane & Nakayama, 2003) and 
endoplasmic reticulum  (Wang et al., 2005). Only the C-terminal tail is membrane anchored 
while the bulk of the protein is exposed to the cytosol. The unique topology of FKBP38 
allows it to juxtapose between cytosolic and ER chaperone proteins. FKBP38 functions as a 
co-chaperone to HSC70/HSP90 complex to mediate proper folding and trafficking of 
membrane proteins like the multidomain cAMP-regulated chloride channel, CFTR (Wang et 
al., 2006) and the voltage-dependent K+ channel, HERG (Walker et al., 2007). The immature 
form of HERG localizes to the endoplasmic reticulum whereas the fully glycosylated mature 
protein is present in the Golgi or the cell surface. While siRNA mediated knockdown of 
FKBP38 reduced HERG maturation, overexpression of FKBP38 was able to rescue the HERG 
F805C trafficking mutant. FKBP38 is involved in the late stages of HERG folding and ER 
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export, as majority of FKBP38 has been found to associate with immature HERG. It is likely 
that natively folded HERG is released from its final chaperone complex while still attached 
with FKBP38. The bound FKBP38 could further mediate the attachment of HERG with the 
motor protein kinesin for transport to the plasma membrane. HERG mutations have been 
associated with the Long QT syndrome, a cardiac disorder characterized by long QT 
intervals. PD patients have an increased susceptibility to cardiac arrest as is evident from a 
prolongation of the QT interval (Hurst et al., 2003). Therefore, it is likely that FKBP38-
mediated HERG trafficking plays an important role in PD pathogenesis.  
3.4 FKBP mediated regulation of Tau function and its effect on microtubule dynamics 
Tau, a member of the microtubule-associated protein family (MAP), binds and stabilizes 
microtubules (MTs) and is therefore intrinsically linked with MT dynamics. Six isoforms of 
tau are present in humans, the longest one having four MT-binding repeat motifs. Normal 
biological functions of tau are dependent on its phosphorylation state. Involvement of tau in 
PD pathogenesis comes from the observations that (1) it accumulates in LBs together with -
SYN (Ishizawa et al., 2003); (2) analysis of synapse-enriched fractions from PD brains show 
an increased phosphorylation for both tau and -SYN (Muntane et al., 2008) and (3) tau and 
synuclein synergistically promote in vitro fibrillization of each other (Giasson et al., 2003). -
SYN mediates tau phosphorylation at Ser262/356 by activating protein kinase A (PKA)(Jensen 
et al., 1999) while in MPTP models of PD, -SYN recruits GSK3 kinase to phosphorylate tau 
at Ser396/404 (Duka et al., 2009). Hyperphosphorylation of tau results in MT destabilization by 
interfering with its binding.  
Recent studies have shown that both FKBP51 (Jinwal et al., 2010) and FKBP52 (Chambraud et 
al., 2007; Chambraud et al., 2010) can interact with tau. FKBP52 preferentially binds to 
hyperphosphorylated tau and colocalizes with tau at the growth cones in both cortical 
neurons and PC12 cells. Interestingly, FKBP52 could inhibit tau-mediated tubulin 
polymerization in vitro. This is consistent with the observation that overexpression of 
FKBP52 impairs neurite outgrowth in cultured neurons (Chambraud et al., 2010). Interaction 
of FKBP52 with tau was mapped to the C-terminal TPR domain of FKBP52 (Chambraud et 
al., 2007). Currently it is not known if the neuroprotection mediated by “anti-tau” activity of 
FKBP52 is linked to proteasomal degradation of hyperphosphorylated tau via enhanced 
trafficking or by increased aggregation of toxic tau into fibrillary tangles.  
FKBP51, a member of the HSP90 chaperone complex, directly associates with tau and its 
overexpression significantly increases the levels of phospho- and total tau in cells.  Contrary 
to FKBP52, FKBP51 enhances the tau-mediated MT polymerization and the PPIase activity 
of FKBP51 is crucial for its function in tau processing. The data by Dickey and coworkers 
suggest a model whereby binding of FKBP51-HSP90 complex to phosphorylated tau 
triggers its dephosphorylation and recycling to the microtubules thereby facilitating MT 
polymerization and stabilization (Jinwal et al., 2010). HSP90-FKBP51 binding also shields tau 
from CHIP (carboxy terminus of the HSC70-interacting protein) mediated ubiquitination 
and subsequent proteasomal degradation (Figure 3). 
3.5 FKBP38 anchors Bcl-2 to the mitochondria and regulates apoptosis 
The C-terminal tail of the noncanonical FKBP, FKBP38, localizes the protein to the ER and 
mitochondrial membrane where it interacts with the anti-apoptotic proteins, Bcl-2 and Bcl-xL 
and regulates their functions. FKB38 is critical for the mitochondrial localization of Bcl-2 and 
Bcl-xL; expression of mitochondrial targeting defective FKBP38 mutants and RNAi mediated  
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Fig. 3. FKBPs regulate microtubule stability by interacting with the microtubule-associated 
protein, tau. FKBP51 and FKBP52 have opposing effects on microtubule (MT) stability. 
FKBP52 exhibits “anti-tau” activity; by sequestering tau, it prevents its association with MT 
thereby destabilizing MTs. Together with the HSP90 complex, FKBP51 binds 
phosphorylated tau in its trans-conformation, isomerizes it to the cis-form and recycles it 
back to the MTs. Alternatively FKBP51 can accelerate aggregation of phospho-tau species.  
Phospho-tau can also be degraded by the cellular proteasomal system following CHIP-
mediated polyubiquitination. Binding of FKBP51 and CHIP to phosphorylated tau is 
mutually exclusive. By recruiting PKA/GSK3, -SYN promotes tau-phosphorylation 
within the MT-binding domain and its subsequent removal from MTs. Activity of -SYN is 
in turn regulated by the E3 ubiquitin ligase, Parkin. By inhibiting PLK2 kinase and 
enhancing PP2A phosphatase activity, Parkin decreases -SYN phosphorylation and 
interferes with its activity. 
knockdown of FKBP38 causes the cellular redistribution of these proteins. Furthermore 
FKBP38-mediated mitochondrial targeting is responsible for the anti-apoptotic activity of 
FKBP38 (Shirane & Nakayama, 2003; Kang et al., 2005). Nishimura and colleagues have 
shown FKBP38 is a bona fide substrate for the aspartyl protease, presenilin 1 and 2 (PS1/2) 
(Wang et al., 2005). Under physiological conditions PS1/2 forms macromolecular 
heteromeric complexes with FKBP38 and Bcl-2 and sequesters them in the ER/Golgi via a -
secretase independent mechanism. Thus by inhibiting the FKBP38 mediated mitochondrial 
targeting of Bcl-2, PS1/2 antagonizes the anti-apoptotic effect of FKBP38.  
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In neuroblastoma cells, FKBP38 exhibits Ca2+/CaM stimulated PPIase activity and the 
FKBP38/Ca2+/CaM ternary complex binds Bcl-2. This binding is interrupted by GPI-1046, 
indicating that the active site of FKBP38 is involved in Bcl-2 interaction. HSP90 in the 
HSP90/Bcl-2/Ca2+/CaM ternary complex has also been shown to inhibit the Bcl-2-FKBP38 
interaction by blocking access to the enzyme active site (Edlich et al., 2007). GPI-1046 and 
RNAi-mediated depletion of FKBP38 activity was able to promote neuronal cell survival 
thus indicating that, in neuronal cells, FKBP38 has proapoptotic function. This observation 
contradicts earlier reports wherein it was shown that FKBP38 has anti-apoptotic effect 
(Shirane & Nakayama, 2003; Kang et al., 2005). One plausible explanation for this 
discrepancy could be explained on the basis of the different cell lines, neuronal versus non-
neuronal, used in these studies. The potent neuroprotective and neuroregenerative effects of 
low molecular weight FKBP38 inhibitors in neuroblastoma cells concur well with the 
proapoptotic role of FKBP38. Furthermore, the ability of the FKBP38 inhibitor - N-(N′,N′-
dimethylcarboxamidomethyl)-cycloheximide to elicit neural stem proliferation and 
neuronal differentiation in a rat model of transient cerebral ischemia underscores the 
importance of FKBP38 in neuronal apoptosis (Edlich et al., 2006). 
4. Neuroimmunophilin ligands as therapeutics for PD 
Currently available drugs aimed at PD treatment do not have the capacity to inhibit PD 
progression but can only alleviate symptoms and/or delay neuronal atrophy by altering 
neurotransmitter metabolism. Neuroimmunophilin ligands are non-immunosuppressive 
and mediate the beneficial effects by multiple mechanisms that include inhibition of 
apoptosis, increased neurotrophic signaling and/or reducing oxidative stress by interfering 
with mitochondrial dysfunction (Tanaka & Ogawa, 2004). Several groups have reported that 
NILs like FK506, GPI-1046 and V-10367 (Figure 4A) promote striatal dopaminergic 
innervations in MPTP- or 6-OHDA models of PD (Kitamura et al., 1994; Steiner et al., 1997; 
Costantini et al., 1998; Guo et al., 2001). Studies have also shown that GPI-1046 protects 
against the p-chloroamphetamine-induced destruction of central serotoninergic neurons and  
 
 
Fig. 4. (A) Structure of the neuroimmunophilin ligand FK506 and its non-
immunosuppressive derivatives, GPI-1046 and V-10367. (B) Binding of FK506 (green) into 
the active site pocket of FKBP12 “(represented by cartoon model).  
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senescence-related atrophy of medial septal cholinergic neurons (Sauer et al., 1999). 
Furthermore, rotational behavior and loss of corticostriatal long-term potentiation (LTP) in 
6-OHDA treated rats was alleviated by GPI-1046. However, as similar efficacy was obtained 
with an analog that does not bind FKBP12 (V-13670), the importance of FKBP12 in 
mediating neurotrophic effects is debatable. Besides FK506 derivatives, CsA has been shown 
to protect against dopaminergic degeneration, promote regeneration of DA neurons and 
even suppress microglial cytotoxicity, as activated microglia has been known to generate 
free radicals (Banati et al., 1993).  
The binding mode of FK506 and its non-immunosuppressive counterpart, GPI-1046 has 
been elucidated (Van Duyne et al., 1993; Sich et al., 2000). Minimal binding motif comprises 
of the central pipecolic acid ring, the -dicarbonyl amide linkage and pyranose ring. In the 
FK506-FKBP12 crystal structure (Van Duyne et al., 1993), the pipecoline ring sits in the cavity 
defined by Trp59 and Tyr26, Phe46, Val55, Ile56, Phe99 side chains, whereas the -dicarbonyl 
amide is hydrogen-bonded to –COOH and –OH group of Asp37 and Tyr82, respectively 
(Figure 4B). The hydrophobic pocket formed by Phe36, Asp37, Tyr82, His87, Ile90 and Ile91 
buries the pyranose ring while the cyclohexyl ester chain is engaged in hydrophobic 
interactions within a shallow surface groove. SAR studies have shown that the -dicarbonyl 
amide functionality is indispensible for enzyme inhibition as replacement of either one or 
both carbonyl groups reduces potency. Similarly, pipecolic ring opening drastically 
increases the inhibition constant of the derivatives. GPI-1046 binds in a manner analogous to 
that of FK506 with the amide bond in trans configuration; the only exception being the 
replacement of pipecolyl moiety of FK506 by the prolyl ring of GPI-1046. Even though GPI-
1046 has fewer favorable protein-ligand interactions, its effect on protein dynamics is 
essentially same as FK506, that is, stabilize the conformation of solvent exposed residues 
that are important in protein-protein and protein-ligand interactions. 
The therapeutic utility of NILs has been questioned by work from other groups (Harper et al., 
1999; Parker et al., 2000; Bocquet et al., 2001) as many of the initial observations could not be 
replicated in identical systems. For instance, Harper and colleagues observed that GPI-1046 
causes only a marginal increase in neurite outgrowth of chick dorsal root ganglia in culture 
under conditions where a very robust effect of nerve growth factor was seen. GPI-1046 did not 
restore tyrosine hydroxylase-positive fibers after 6-OHDA administration neither did it protect 
cultured dopaminergic neurons against MPTP induced toxicity. One possibility for the 
observed differences could be the levels of dopaminergic dysfunction. GPI-1046 provided 
neuroprotection in cases when the degradation was mild to moderate; it has no effect in severe 
cases when DA neuron levels deplete to 20% of that in normal controls. Other parameters like 
variability in culture conditions, differences in days in vitro prior to experimentation, can 
potentially account for the contrasting observations (Pong and Zaleska, 2003). Furthermore, 
neuroprotective effects of GPI-1046 could not be replicated in monkey model of MPTP toxicity 
(Emborg et al., 2001) suggesting species-specific differences with respect to GPI-1046 activity.  
5. Conclusion 
FKBPs have emerged as novel cellular target for treatment of Parkinson’s disease and other 
neurological disorders. The extraordinary unmet need for therapeutic intervention in PD 
continues to drive the search for potential drug candidates. Non-immunosuppressive NILs 
with their small size, target specificity, bioavailability and stability provide excellent 
scaffolds for the development of new drugs. Although our present knowledge of the mode 
of action of NILs is still fragmentary, there is increasing evidence that the neurotrophic, 
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neuroprotective and restorative potential of these compounds is mediated by signaling 
pathways that can have antagonistic or additive effect.  For example, multiple pathways 
may crosstalk via common integral components such as c-Jun (Gold et al., 1999; Winter et al., 
2000). So far, the nervous system has been found to be enriched in only five FKBPs – FKBP-
12, -38, -51, -52 and -65. Much work needs to be done so as to identify unique 
neuroimmunophilins and their interacting partners, assess their cellular function as well as 
their response to injury. Furthermore, issues such as reproducibility of pre-clinical data, 
structure-activity relationship studies, drug evaluation in appropriate animal models, and 
implementation of proper clinical designs and endpoints needs immediate attention as such 
information will aid in the development of novel NILs with improved efficacies, target 
selectivity and potency. FKBPs and NILs seem to be a promising area for therapeutic 
intervention of PD and other neurodegenerative disorders. 
6. Acknowledgment 
The authors would like to acknowledge the support from Ministry of Health-National 
Medical Research Council, Singapore for funding (NMRC/1177/2008).  
7. References 
Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M. & Bonini, N.M. (2002). Chaperone 
suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's 
disease. Science, Vol 295, pp 865-868. 
Avramut, M. & Achim, C.L. (2002). Immunophilins and their ligands: insights into survival 
and growth of human neurons. Physiol Behav, Vol 77, pp 463-468. 
Banati, R.B., Gehrmann, J., Schubert, P. & Kreutzberg, G.W. (1993). Cytotoxicity of microglia. 
Glia, Vol 7, pp 111-118. 
Barik, S. (2006). Immunophilins: for the love of proteins. Cell Mol. Life Sci., Vol 63, pp 2889-2900. 
Bocquet, A., Lorent, G., Fuks, B., Grimee, R., Talaga, P., Daliers, J. & Klitgaard, H. (2001). 
Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur. 
J Pharmacol., Vol 415, pp 173-180. 
Chambraud, B., Belabes, H., Fontaine-Lenoir, V., Fellous, A. & Baulieu, E.E. (2007). The 
immunophilin FKBP52 specifically binds to tubulin and prevents microtubule 
formation. FASEB J., Vol 21, pp 2787-2797. 
Chambraud, B., Sardin, E., Giustiniani, J., Dounane, O., Schumacher, M., Goedert, M. & 
Baulieu, E.E. (2010). A role for FKBP52 in Tau protein function. Proc. Natl. Acad. Sci. 
USA, Vol 107, pp 2658-2663. 
Charters, A.R., Kobayashi, M. & Butcher, S.P. (1994). Immunochemical analysis of FK506 binding 
proteins in neuronal cell lines and rat brain. Biochem. Soc. Trans., Vol 22, pp 411S. 
Coss, M.C., Stephens, R.M., Morrison, D.K., Winterstein, D., Smith, L.M. & Simek, S.L. 
(1998). The immunophilin FKBP65 forms an association with the serine/threonine 
kinase c-Raf-1. Cell Growth Differ., Vol 9, pp 41-48. 
Costantini, L.C., Chaturvedi, P., Armistead, D.M., McCaffrey, P.G., Deacon, T.W. & Isacson, 
O. (1998). A novel immunophilin ligand: distinct branching effects on 
dopaminergic neurons in culture and neurotrophic actions after oral administration 
in an animal model of Parkinson's disease. Neurobiol. Dis Vol 5, pp 97-106. 
Dawson, T.M., Steiner, J.P., Lyons, W.E., Fotuhi, M., Blue, M. & Snyder, S.H. (1994). The 
immunophilins, FK506 binding protein and cyclophilin, are discretely localized in 
the brain: relationship to calcineurin. Neuroscience, Vol 62, pp 569-580. 
www.intechopen.com
 Role of FKBPs in Parkinson’s Disease 
 
185 
Dawson, T.M. (2006). Parkin and defective ubiquitination in Parkinson's disease. J. Neural 
Transm. Suppl, Vol 209-213. 
Duka, T., Duka, V., Joyce, J.N. & Sidhu, A. (2009). Alpha-Synuclein contributes to GSK-
3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J, Vol  
23, pp 2820-2830. 
Edlich, F., Weiwad, M., Erdmann, F., Fanghanel, J., Jarczowski, F., Rahfeld, J.U. & Fischer, G. 
(2005). Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin. EMBO J, Vol 24, 
pp 2688-2699. 
Edlich, F., Weiwad, M., Wildemann, D., Jarczowski, F., Kilka, S., Moutty, M.C., Jahreis, G., 
Lucke, C., Schmidt, W., Striggow, F. & Fischer, G. (2006). The specific FKBP38 
inhibitor N-(N',N'-dimethylcarboxamidomethyl)cycloheximide has potent 
neuroprotective and neurotrophic properties in brain ischemia. J Biol. Chem.  Vol 
281, pp 14961-14970. 
Edlich, F., Erdmann, F., Jarczowski, F., Moutty, M.C., Weiwad, M. & Fischer, G. (2007). The 
Bcl-2 regulator FKBP38-calmodulin-Ca2+ is inhibited by Hsp90. J Biol. Chem., Vol 
282, pp 15341-15348. 
Emborg, M.E., Shin, P., Roitberg, B., Sramek, J.G., Chu, Y., Stebbins, G.T., Hamilton, J.S., 
Suzdak, P.D., Steiner, J.P. & Kordower, J.H. (2001). Systemic administration of the 
immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp. Neurol., Vol  168, 
pp 171-182. 
Eriksen, J.L., Wszolek, Z. & Petrucelli, L. (2005). Molecular pathogenesis of Parkinson 
disease. Arch. Neurol. Vol 62, pp 353-357. 
Funauchi, M., Haruta, H. & Tsumoto, T. (1994). Effects of an inhibitor for 
calcium/calmodulin-dependent protein phosphatase, calcineurin, on induction of 
long-term potentiation in rat visual cortex. Neurosci. Res., Vol 19, pp 269-278. 
Fusco, D., Vargiolu, M., Vidone, M., Mariani, E., Pennisi, L.F., Bonora, E., Capellari, S., 
Dirnberger, D., Baumeister, R., Martinelli, P. & Romeo, G. (2010). The 
RET51/FKBP52 complex and its involvement in Parkinson disease. Hum. Mol. 
Genet., Vol 19, pp 2804-2816. 
Gerard, M., Debyser, Z., Desender, L., Kahle, P.J., Baert, J., Baekelandt, V. & Engelborghs, Y. 
(2006). The aggregation of alpha-synuclein is stimulated by FK506 binding proteins 
as shown by fluorescence correlation spectroscopy. FASEB J., Vol 20, pp 524-526. 
Gerard, M., Debyser, Z., Desender, L., Baert, J., Brandt, I., Baekelandt, V. & Engelborghs, Y. 
(2008). FK506 binding protein 12 differentially accelerates fibril formation of wild 
type alpha-synuclein and its clinical mutants A30P or A53T. J Neurochem., Vol 106, 
pp 121-133. 
Gerard, M., Deleersnijder, A., Daniels, V., Schreurs, S., Munck, S., Reumers, V., Pottel, H., 
Engelborghs, Y., Van den Haute, C., Taymans, J.M., Debyser, Z. & Baekelandt, V. 
(2010). Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation 
and Parkinson's disease-like pathology. J Neurosci., Vol 30, pp 2454-2463. 
Gerlach, M., Riederer, P., Przuntek, H. & Youdim, M.B. (1991). MPTP mechanisms of 
neurotoxicity and their implications for Parkinson's disease. Eur. J Pharmacol., Vol 
208, pp 273-286. 
Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T., 
Trojanowski, J.Q. & Lee, V.M. (2003). Initiation and synergistic fibrillization of tau 
and alpha-synuclein. Science, Vol 300, pp 636-640. 
Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C. & Gage, F.H. (2010). Mechanisms 
underlying inflammation in neurodegeneration. Cell, Vol 140, pp 918-934. 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
186 
Goedert, M. (2001). Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 
Vol 2, pp 492-501. 
Gold, B.G. (1997). FK506 and the role of immunophilins in nerve regeneration. Mol. 
Neurobiol., Vol 15, pp 285-306. 
Gold, B.G. & Nutt, J.G. (2002). Neuroimmunophilin ligands in the treatment of Parkinson's 
disease. Curr. Opin. Pharmacol., Vol  2, pp 82-86. 
Gold, B.G., Densmore, V., Shou, W., Matzuk, M.M. & Gordon, H.S. (1999). Immunophilin 
FK506-binding protein 52 (not FK506-binding protein 12) mediates the 
neurotrophic action of FK506. J Pharmacol. Exp. Ther., Vol 289, pp 1202-1210. 
Guo, X., Dawson, V.L. & Dawson, T.M. (2001). Neuroimmunophilin ligands exert 
neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur. J 
Neurosci., Vol 13, pp 1683-1693. 
Hamilton, G.S. & Steiner, J.P. (1998). Immunophilins: beyond immunosuppression. J Med. 
Chem., Vol 41, pp 5119-5143. 
Harper, S., Bilsland, J., Young, L., Bristow, L., Boyce, S., Mason, G., Rigby, M., Hewson, L., 
Smith, D., O'Donnell, R., O'Connor, D., Hill, R.G., Evans, D., Swain, C., Williams, B. 
& Hefti, F. (1999). Analysis of the neurotrophic effects of GPI-1046 on neuron 
survival and regeneration in culture and in vivo. Neuroscience, Vol 88, pp 257-267. 
Hodgkiss, J.P. & Kelly, J.S. (1995). Only 'de novo' long-term depression (LTD) in the rat 
hippocampus in vitro is blocked by the same low concentration of FK506 that 
blocks LTD in the visual cortex. Brain Res., Vol 705, pp 241-246. 
Hurst, R.S., Higdon, N.R., Lawson, J.A., Clark, M.A., Rutherford-Root, K.L., McDonald, W.G., 
Haas, J.V., McGrath, J.P. & Meglasson, M.D. (2003). Dopamine receptor agonists 
differ in their actions on cardiac ion channels. Eur. J Pharmacol., Vol 482, pp 31-37. 
Ischiropoulos, H. (2003). Oxidative modifications of alpha-synuclein. Ann. N. Y. Acad. Sci., 
Vol 991, pp 93-100. 
Ishizawa, T., Mattila, P., Davies, P., Wang, D. & Dickson, D.W. (2003). Colocalization of tau and 
alpha-synuclein epitopes in Lewy bodies. J Neuropathol. Exp. Neurol., Vol 62, pp 389-397. 
Jensen, P.H., Hager, H., Nielsen, M.S., Hojrup, P., Gliemann, J. &  Jakes, R. (1999). Alpha-
synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau 
phosphorylation of serine residues 262 and 356. J Biol. Chem., Vol 274, pp 25481-25489. 
Jinwal, U.K., Koren, J., Borysov, S.I., Schmid, A.B., Abisambra, J.F., Blair, L.J., Johnson, A.G., 
Jones, J.R., Shults,  C.L., O'Leary, J.C., Jin, Y., Buchner, J., Cox, M.B. & Dickey, C.A. 
(2010). The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes 
microtubules. J Neurosci., Vol 30, pp 591-599. 
Kang, C.B., Feng, L., Chia, J. & Yoon, H.S. (2005). Molecular characterization of FK-506 
binding protein 38 and its potential regulatory role on the anti-apoptotic protein 
Bcl-2. Biochem. Biophys. Res. Commun., Vol 337, pp 30-38. 
Khandelwal, P.J., Dumanis, S.B., Feng, L.R., Maguire-Zeiss, K., Rebeck, G., Lashuel, H.A. & 
Moussa, C.E. (2010). Parkinson-related parkin reduces alpha-Synuclein 
phosphorylation in a gene transfer model. Mol. Neurodegener. Vol  5, pp 47. 
Kitamura, Y., Itano, Y., Kubo, T. & Nomura, Y. (1994). Suppressive effect of FK-506, a novel 
immunosuppressant, against MPTP-induced dopamine depletion in the striatum of 
young C57BL/6 mice. J Neuroimmunol., Vol  50, pp 221-224. 
Kopito, R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol., 
Vol 10, pp 524-530. 
Kragh, C.L., Lund, L.B., Febbraro, F., Hansen, H.D., Gai, W.P., El-Agnaf, O., Richter-Landsberg, 
C. & Jensen, P.H. (2009). {alpha}-Synuclein Aggregation and Ser-129 Phosphorylation-
dependent Cell Death in Oligodendroglial Cells. J Biol. Chem., Vol 284, pp 10211-10222. 
www.intechopen.com
 Role of FKBPs in Parkinson’s Disease 
 
187 
Lyons, W.E., George, E.B., Dawson, T.M., Steiner, J.P. & Snyder, S.H. (1994). 
Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells 
and sensory ganglia. Proc. Natl. Acad. Sci. USA, Vol 91, pp 3191-3195. 
Maki, N., Sekiguchi, F., Nishimaki, J., Miwa, K., Hayano, T., Takahashi, N. & Suzuki, M. 
(1990). Complementary DNA encoding the human T-cell FK506-binding protein, a 
peptidylprolyl cis-trans isomerase distinct from cyclophilin. Proc. Natl. Acad. Sci. 
USA, Vol 87, pp 5440-5443. 
Mandel, S., Grunblatt, E., Riederer, P., Amariglio, N., Jacob-Hirsch, J., Rechavi, G. & 
Youdim, M.B. (2005). Gene expression profiling of sporadic Parkinson's disease 
substantia nigra pars compacta reveals impairment of ubiquitin-proteasome 
subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. N. Y. 
Acad. Sci., Vol 1053, pp 356-375. 
McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. (1988). Reactive microglia are positive 
for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. 
Neurology, Vol 38, pp 1285-1291. 
Meiri, K.F., Bickerstaff, L.E. & Schwob, J.E. (1991). Monoclonal antibodies show that kinase 
C phosphorylation of GAP-43 during axonogenesis is both spatially and temporally 
restricted in vivo. J Cell Biol., Vol  112, pp 991-1005. 
Meuvis, J., Gerard, M., Desender, L., Baekelandt, V. & Engelborghs, Y. (2010). The 
conformation and the aggregation kinetics of alpha-synuclein depend on the 
proline residues in its C-terminal region. Biochemistry, Vol 49, pp 9345-9352. 
Muchowski, P.J. (2002). Protein misfolding, amyloid formation, and neurodegeneration: a 
critical role for molecular chaperones? Neuron, Vol 35, pp 9-12. 
Muntane, G., Dalfo, E., Martinez, A. & Ferrer, I. (2008). Phosphorylation of tau and alpha-
synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease 
and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience, Vol 
152, pp 913-923. 
Nagatsu, T. & Sawada, M. (2005) Inflammatory process in Parkinson's disease: role for 
cytokines. Curr. Pharm. Des., Vol 11, pp 999-1016. 
Nichols, R.A., Suplick, G.R. & Brown, J.M. (1994). Calcineurin-mediated protein 
dephosphorylation in brain nerve terminals regulates the release of glutamate. J 
Biol. Chem., Vol 269, pp 23817-23823. 
Nilsson, A., Skold, K., Sjogren, B., Svensson, M., Pierson, J., Zhang, X., Caprioli, R.M., Buijs, 
J., Persson, B., Svenningsson, P & Andren, P.E. (2007). Increased striatal mRNA and 
protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease 
and identification of FKBP-12-binding proteins. J Proteome Res., Vol 6, pp 3952-3961. 
Parker, E.M., Monopoli, A., Ongini, E., Lozza, G. & Babij. C.M. (2000). Rapamycin, but not 
FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell 
cycle progression. Neuropharmacology, Vol  39, pp 1913-1919. 
Pong, K. & Zaleska, M.M. (2003). Therapeutic implications for immunophilin ligands in the 
treatment of neurodegenerative diseases. Curr. Drug Targets CNS Neurol. Disord ., 
Vol 2, pp 349-356. 
Poon, H.F., Shepherd, H.M., Reed, T.T., Calabrese, V., Stella, A.M., Pennisi, G., Cai, J., Pierce, 
W.M., Klein, J.B. & Butterfield, D.A. (2006). Proteomics analysis provides insight into 
caloric restriction mediated oxidation and expression of brain proteins associated 
with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate 
dysregulation and impaired protein synthesis. Neurobiol. Aging.,Vol 27, pp 1020-1034. 
Sauer, H., Francis, J.M., Jiang, H., Hamilton, G.S. & Steiner, J.P. (1999). Systemic 
treatment with GPI 1046 improves spatial memory and reverses cholinergic 
www.intechopen.com
 Mechanisms in Parkinson’s Disease – Models and Treatments 
 
188 
neuron atrophy in the medial septal nucleus of aged mice. Brain Res., Vol  842, 
pp 109-118. 
Sharkey, J. & Butcher, S.P. (1994). Immunophilins mediate the neuroprotective effects of 
FK506 in focal cerebral ischaemia. Nature, Vol 371, pp 336-339. 
Sharma, V.K., Li, B., Khanna, A., Sehajpal, P.K. & Suthanthiran, M. (1994). Which way for 
drug-mediated immunosuppression? Curr. Opin. Immunol., Vol 6, pp 784-790. 
Shirane, M. & Nakayama, K.I. (2003). Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to 
mitochondria and inhibits apoptosis. Nat. Cell Biol., Vol 5, pp 28-37. 
Sich, C., Improta, S., Cowley, D.J., Guenet, C., Merly, J.P., Teufel, M & Saudek, V. (2000). 
Solution structure of a neurotrophic ligand bound to FKBP12 and its effects on 
protein dynamics. Eur. J Biochem., Vol  267, pp 5342-5355. 
Snyder, S.H. (1992). Nitric Oxide: first in a new class of neurotransmitters. Science, Vol 257, 
pp 494-496. 
Snyder, S.H., Lai, M.M. & Burnett, P.E. (1998). Immunophilins in the nervous system. 
Neuron, Vol 21, pp 283-294. 
Steiner, J.P., Dawson, T.M., Fotuhi, M., Glatt, C.E., Snowman, A.M., Cohen, N & Snyder, 
S.H. (1992). High brain densities of the immunophilin FKBP colocalized with 
calcineurin. Nature, Vol  358, pp 584-587. 
Steiner, J.P., Dawson, T.M., Fotuhi, M & Snyder, S.H. (1996). Immunophilin regulation of 
neurotransmitter release. Mol. Med., Vol 2, pp 325-333. 
Steiner, J.P., Hamilton, G.S., Ross, D.T., Valentine, H.L., Guo, H., Connolly, M.A., Liang, S., 
Ramsey, C., Li, J.H., Huang, W., Howorth, P., Soni, R., Fuller, M., Sauer, H., 
Nowotnik, A.C. & Suzdak, P.D. (1997). Neurotrophic immunophilin ligands 
stimulate structural and functional recovery in neurodegenerative animal models. 
Proc. Natl. Acad. Sci. USA, Vol 94, pp 2019-2024. 
Tanaka, K. & Ogawa, N. (2004). Possibility of non-immunosuppressive immunophilin 
ligands as potential therapeutic agents for Parkinson's disease. Curr. Pharm. Des., 
Vol 10, pp 669-677. 
Tong, G., Shepherd, D. & Jahr, C.E. (1995). Synaptic desensitization of NMDA receptors by 
calcineurin. Science, Vol  267, pp 1510-1512. 
Tong, Y. & Shen, J. (2009). Alpha-synuclein and LRRK2: partners in crime. Neuron, Vol 64, 
pp 771-773. 
Van Duyne, G.D., Standaert, R.F., Karplus, P.A., Schreiber, S.L. & Clardy, J. (1993). Atomic 
structures of the human immunophilin FKBP-12 complexes with FK506 and 
rapamycin. J Mol. Biol., Vol  229, pp 105-124. 
Walker, V.E., Atanasiu, R., Lam, H. & Shrier, A. (2007). Co-chaperone FKBP38 promotes 
HERG trafficking. J Biol. Chem., Vol  282, pp 23509-23516. 
Wang, H.Q., Nakaya, Y., Du, Z., Yamane, T., Shirane, M., Kudo, T., Takeda, M., 
Takebayashi, K., Noda, Y., Nakayama, K.I. & Nishimura, M. (2005). Interaction of 
presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. 
Hum. Mol. Genet., Vol 14, pp 1889-1902. 
Wang, X., Venable, J., LaPointe, P., Hutt, D.M., Koulov, A.V., Coppinger, J., Gurkan, C., 
Kellner, W., Matteson, J., Plutner, H., Riordan, J.R., Kelly, J.W., Yates, JR. & Balch, 
W.E. (2006). Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR 
in cystic fibrosis. Cell, Vol 127, pp 803-815. 
Winter, C., Schenkel, J., Burger, E., Eickmeier, C., Zimmermann, M & Herdegen, T. (2000). 
The immunophilin ligand FK506, but not GPI-1046, protects against neuronal death 
and inhibits c-Jun expression in the substantia nigra pars compacta following 
transection of the rat medial forebrain bundle. Neuroscience, Vol 95, pp 753-762. 
www.intechopen.com
Mechanisms in Parkinson's Disease - Models and Treatments
Edited by Dr. Juliana Dushanova
ISBN 978-953-307-876-2
Hard cover, 582 pages
Publisher InTech
Published online 08, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra.
Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main
obstacle to developing neuroprotective therapies is a limited understanding of the key molecular mechanisms
that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of
proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously
implicated culprits in PD neurodegeneration, mitochondrial dysfunction, and oxidative stress may also act in
part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in
dopaminergic neurons. Neurotoxin-based models have been important in elucidating the molecular cascade of
cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable
in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic
neurons to the degenerative process.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Souvik Chattopadhaya, Amaravadhi Harikishore and Ho Sup Yoon (2012). Role of FKBPs in Parkinson’s
Disease, Mechanisms in Parkinson's Disease - Models and Treatments, Dr. Juliana Dushanova (Ed.), ISBN:
978-953-307-876-2, InTech, Available from: http://www.intechopen.com/books/mechanisms-in-parkinson-s-
disease-models-and-treatments/role-of-fkbps-in-parkinson-s-disease
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
